Malignant melanoma and Mobility decreased
Summary:
Mobility decreased is found among people with Malignant melanoma, especially for people who are male, 60+ old.
The study analyzes which people have Mobility decreased with Malignant melanoma. It is created by eHealthMe based on reports of 45 people who have Malignant melanoma from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.
What is Malignant melanoma?
Malignant melanoma (skin cancer rises from melancytes) is found to be associated with 789 drugs and 740 conditions by eHealthMe. Check the latest studies of Malignant melanoma.
What is Mobility decreased?
Mobility decreased (ability to move is reduced) is found to be associated with 1,778 drugs and 1,632 conditions by eHealthMe. Check the latest studies of Mobility decreased.
45 people who have Malignant Melanoma and Mobility Decreased are studied.

Gender of people who have Malignant Melanoma and experienced Mobility Decreased *:
- female: 37.21 %
- male: 62.79 %
Age of people who have Malignant Melanoma and experienced Mobility Decreased *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 5.5600000000000005 %
- 30-39: 5.5600000000000005 %
- 40-49: 13.89 %
- 50-59: 8.33 %
- 60+: 66.67 %
Common co-existing conditions for these people *:
- Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 2 people, 4.44%
- Hypersensitivity: 2 people, 4.44%
- High Blood Pressure: 2 people, 4.44%
- Tumor Pain: 1 person, 2.22%
- Nausea (feeling of having an urge to vomit): 1 person, 2.22%
- Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 2.22%
- Cancer Pain: 1 person, 2.22%
- Blood Pressure Abnormal: 1 person, 2.22%
- Back Disorder: 1 person, 2.22%
- Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 1 person, 2.22%
Common drugs taken by these people *:
- Tafinlar: 8 people, 17.78%
- Mekinist: 8 people, 17.78%
- Mektovi: 6 people, 13.33%
- Braftovi: 6 people, 13.33%
- Opdivo: 5 people, 11.11%
- Yervoy: 5 people, 11.11%
- Keytruda: 4 people, 8.89%
- Flomax: 3 people, 6.67%
- Zelboraf: 3 people, 6.67%
- Lasix: 2 people, 4.44%
Common symptoms for these people *:
- Fatigue (feeling of tiredness): 19 people, 42.22%
- Weakness: 14 people, 31.11%
- Dizziness: 14 people, 31.11%
- Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 11 people, 24.44%
- Nausea And Vomiting: 10 people, 22.22%
- Rashes (redness): 9 people, 20.00%
- Pain: 8 people, 17.78%
- Nausea (feeling of having an urge to vomit): 8 people, 17.78%
- Weight Decreased: 8 people, 17.78%
- Fever: 7 people, 15.56%
* Approximation only. Some reports may have incomplete information.
Do you take medications and have Mobility decreased?
- Check whether Mobility decreased is associated with a drug or a conditionRelated studies:
Treatments, associated drugs and conditions:
- Malignant melanoma (60,273 reports)
- Mobility decreased (83,538 reports)
All the drugs that are associated with Mobility decreased:
- Mobility decreased (1,778 drugs)
All the conditions that are associated with Mobility decreased:
- Mobility decreased (1,632 conditions)
How the study uses the data?
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
The study is based on Mobility decreased and Malignant melanoma, and their synonyms.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Crysvita cause Death? - a second ago
- Drug interactions of Cortril and Januvia - 3 seconds ago
- Could Abilify cause Hepatocellular Injury? - 5 seconds ago
- Could Crysvita cause Bone Pain? - 7 seconds ago
- Drug interactions of Trelegy Ellipta and Qvar Redihaler - 23 seconds ago
- Could Profen cause Injection Site Reaction? - 33 seconds ago
- Could Adderall cause Acute Psychosis? - 44 seconds ago
- Drug interactions of Trazodone Hydrochloride and Ramipril - 45 seconds ago
- Could Lansoprazole cause Dry Eyes? - 45 seconds ago
- Stroke and Dyslipidaemia - 53 seconds ago